Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

BACKGROUND: Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt...

Descripción completa

Detalles Bibliográficos
Autores principales: Nannini, M., Rizzo, A., Nigro, M.C., Vincenzi, B., Mazzocca, A., Grignani, G., Merlini, A., D’Ambrosio, L., Tolomeo, F., Badalamenti, G., Incorvaia, L., Bonasera, A., Fumagalli, E., Miliziano, D., Ligorio, F., Brunello, A., Chiusole, B., Gasperoni, S., Novelli, M., Pantaleo, M.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350191/
https://www.ncbi.nlm.nih.gov/pubmed/34352702
http://dx.doi.org/10.1016/j.esmoop.2021.100222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350191/
https://www.ncbi.nlm.nih.gov/pubmed/34352702
http://dx.doi.org/10.1016/j.esmoop.2021.100222

Ejemplares similares